Early-Stage Breast Cancer: RxPONDER and Node-Positive Disease

Dr. Allison DiPasquale and Dr. Sonya Reid discuss how findings from the RxPONDER trial have influenced treatment decision-making for patients with early-stage HR-positive, HER2-negative, node-positive breast cancer. Dr. Reid reviews the key clinical findings, explaining that the addition of chemotherapy to endocrine therapy improved outcomes in premenopausal women with one to three positive lymph nodes, whereas postmenopausal women with similar disease characteristics did not derive the same benefit. The faculty then explore the potential biological mechanisms underlying these observations, including the ongoing discussion regarding the contribution of chemotherapy-induced ovarian suppression. Dr. Reid highlights ongoing clinical research that aims to clarify whether ovarian function suppression alone may provide comparable benefit for selected premenopausal patients. Until additional evidence becomes available, she emphasizes that current treatment recommendations continue to support the use of chemotherapy in eligible premenopausal patients. The discussion underscores the evolving role of clinical trial evidence in personalizing treatment strategies for early-stage breast cancer.